



Residual Volume	Treatment Group (N)	6MWT Median Change from Baseline (meters)	6MWT Median Difference (Coil Treatment vs. Control) [95% CI] (meters)
RV ≥ 225%	Control (N=120)	-8.6 (-43.3, 24.4)	23.8 [7.4, 39.6]
	Coil Treatment (N=115)	15.0 (-31.1, 56.0)	
	Crossover (N=47)	-18.29	N/A
RV < 225%	Control (N=37)	0.0 (-38.0, 50.3)	-12.9 [-42.1, 17.0]
	Coil Treatment (N=43)	-9.8 (-36.0, 25.6)	
	Crossover (N=33)	-9.8	N/A



Crossover RV Change- All



AE- % Subject and % Events

Adverse Events through 12M		% of patients (N)	% of events (N)
AEs	Control	88.5% (139)	30.7% (492)
	Treatment	100% (155)	69.3% (1110)
Lower Respiratory Infections including pneumonia	Control	8.9 % (14)	20.8 % (16)
	Treatment	29.7 % (46)	79.2% (61)
COPD Exacerbations	Control	58% (91)	44.8% (185)
	Treatment	69.7% (108)	55.2% (228)
Respiratory Failure	Control	9.6% (15)	27.5% (19)
	Treatment	25.8% (40)	72.5% (50)
Pneumothorax	Control	0.6% (1)	5.3% (1)
	Treatment	11.6% (18)	94.7% (18)
Hemoptysis	Control	0% (0)	0% (0)
	Treatment	58.7% (91)	100% (140)